aiAntigen

 

Category: Precision Medicine

Exhibitor: ACER INCORPORATED

Booth No: M534

 

Characteristic

 

aiAntigen leverages integrated NGS processing and advanced AI to streamline the path from mutation identification to neoantigen prediction and personalized immunotherapy.
• Precision Discovery: Utilizes proprietary AI technologies to evaluate MHC-peptide on the surface presentation, maximizing the likelihood of T-cell recognition and potent immune activation.
• Clinical Validation: Successfully deployed in Compassionate Use programs with cancer patients, demonstrating a mature, "plug-and-play" workflow between clinical institutions, NGS laboratories, peptide synthesis service provider and cell therapy partners.
• Integrated Monitoring: Features built-in support for ELISpot immune monitoring assays, offering an end-to-end data bridge from initial target prediction to post-treatment immune response evaluation.
This scalable platform is designed to shorten R&D cycles and provide a modular foundation for next-generation personalized cancer vaccines. To translate this innovation into clinical impact, we are seeking strategic collaborations and licensing agreements to expand the application of cancer immunotherapy and clinical development.

 

Other Products

 

• 

  mRNA-AIL-111 LNP platform

• 

  Targeted LNP Platform (AIL-111 tLNP)

 

 

 

Back